It is increasingly evident that in some tumors, in which angiogenesis is thwarted genetically or pharmacologically, cancer cells could adapt by migrating more aggressively into normal tissue, based on several pre-existing invasion programmes such as epithelial-mesenchymal transition (EMT) and MMP2/MMP9 secretion [26, 27], or by switching on several distinctive programmes which were currently unknown [28]. The gene discussed is MMP9; the disease is cancer.